LobbyingSave Rare Treatments Task Force lobbying by quarter
Save Rare Treatments Task Force's latest lobbying report covers Q2 2026, at $40K. The four quarters Q4 2025–Q3 2026 total $130K. Its first report covers Q4 2023; the issues it reports most are Health Issues.
Save Rare Treatments Task Force
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $130K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2023 | $10K | 1 |
| Q1 2024 | $30K | 1 |
| Q2 2024 | $80K | 1 |
| Q3 2024 | $70K | 1 |
| Q4 2024 | $40K | 1 |
| Q1 2025 | $40K | 1 |
| Q2 2025 | $80K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $40K | 1 |
| Q1 2026 | $50K | 1 |
| Q2 2026 | $40K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$530K · 11 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES11 reports
- SENATE11 reports
Firms it paid
| Firm | ||
|---|---|---|
| Leavitt Partners | $530K | 11 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JOSH TRENT | Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel | Q2 2026 |
| ROBERT CLAYTON ALSPACH | Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C | Q2 2026 |
| AMY COMSTOCK RICK | Associate Counsel to the President, The White House; Director, US Office of Government Ethics. | Q4 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/15for Q2 | Leavitt Partners | $40K |
| 04/20for Q1 | Leavitt Partners | $50K |
| 01/09for Q4 2025 | Leavitt Partners | $40K |
| 25/10/20for Q3 2025 | Leavitt Partners | $50K |
| 25/07/15for Q2 2025 | Leavitt Partners | $80K |
| 25/04/22for Q1 2025 | Leavitt Partners | $40K |
| 25/01/15for Q4 2024 | Leavitt Partners | $40K |
| 24/10/16for Q3 2024 | Leavitt Partners | $70K |
| 24/07/23for Q2 2024 | Leavitt Partners | $80K |
| 24/04/17for Q1 2024 | Leavitt Partners | $30K |
| 24/01/19for Q4 2023 | Leavitt Partners | $10K |
| 23/12/31for Q4 2023 | Leavitt Partners | Under $5,000 |